Enzon Pharmaceuticals Inc. (OTCMKTS:ENZN) Short Interest Down 97.0% in May

Enzon Pharmaceuticals Inc. (OTCMKTS:ENZN) was the target of a significant drop in short interest in May. As of May 15th, there was short interest totaling 9 shares, a drop of 97.0% from the April 30th total of 300 shares. Approximately 0.0% of the company’s stock are sold short. Based on an average daily trading volume, of 2,945 shares, the days-to-cover ratio is currently 0.0 days.

Enzon Pharmaceuticals Stock Down 0.9%

Shares of OTCMKTS:ENZN traded down $0.05 during mid-day trading on Friday, reaching $5.70. 1,000 shares of the stock were exchanged, compared to its average volume of 1,274. The company has a quick ratio of 1.16, a current ratio of 2.01 and a debt-to-equity ratio of 0.42. The company has a market cap of $4.22 million, a P/E ratio of -0.83 and a beta of -0.03. Enzon Pharmaceuticals has a one year low of $1.50 and a one year high of $12.99. The stock’s 50 day simple moving average is $6.05 and its 200-day simple moving average is $5.52.

Enzon Pharmaceuticals (OTCMKTS:ENZN) last posted its quarterly earnings data on Monday, May 4th. The biotechnology company reported ($0.84) earnings per share (EPS) for the quarter. The company had revenue of $86.54 million during the quarter.

About Enzon Pharmaceuticals

Enzon Pharmaceuticals, Inc, headquartered in Piscataway, New Jersey, is a specialized biopharmaceutical company best known for pioneering polyethylene glycol (PEG) technology to enhance the pharmacokinetic properties of therapeutic proteins. Founded in 1981, Enzon has leveraged its PEGylation platform to develop an array of oncology and hematology products with improved half-life and reduced immunogenicity.

The company’s flagship product, Oncaspar (pegaspargase), was originally approved for the treatment of acute lymphoblastic leukemia in pediatric and adult patients, highlighting Enzon’s commitment to oncology.